Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro

European Journal of Ophthalmology

Volumn 26, Issue 5, 2016, Pages 425-430

  Puddu, Alessandra ^a   Sanguineti, Roberta ^a   Traverso, Carlo Enrico ^a   Viviani, Giorgio L ^a   Nicolò, Massimo ^a,b  

^a Department of Internal Medicine and Medical Specialties ^*  (Italy)

^b Fondazione per la Macula Onlus   (Italy)

Author keywords

Aflibercept; Ranibizumab; Retinal pigment epithelial cells; Vascular endothelial growth factors

Indexed keywords

AFLIBERCEPT; COMPLEMENTARY DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA PIGMENT CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; MACULAR DEGENERATION; METABOLISM; RETINAL PIGMENT EPITHELIUM;

ANGIOGENESIS INHIBITORS; CELL LINE; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MACULAR DEGENERATION; PLACENTA GROWTH FACTOR; RANIBIZUMAB; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL PIGMENT EPITHELIUM; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84984911050     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000786     Document Type: Article

References (26)

1. Bressler NM.Age-related macular degeneration is the leading cause of blindness….JAMA.2004;291(15):1900-1901.
2. Bressler SB.Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.Ophthalmology.2009;116(10)(Suppl):S1-S7.
3. Cao Y.Positive and negative modulation of angiogenesis by VEGFR1 ligands.Sci Signal.2009;2(59):re1.
4. Carmeliet P, Jain RK.Angiogenesis in cancer and other diseases.Nature.2000;407(6801):249-257.
5. Ferrara N, Damico L, Shams N, Lowman H, Kim R.Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.Retina.2006;26(8):859-870.
6. Ohr M, Kaiser PK.Aflibercept in wet age-related macular degeneration: a perspective review.Ther Adv Chronic Dis.2012;3(4):153-161.
7. Krämer I, Lipp HP.Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.J Clin Pharm Ther.2007;32(1):1-14.
8. Holash J, Davis S, Papadopoulos N, et al.VEGF-Trap: a VEGF blocker with potent antitumor effects.Proc Natl Acad Sci U S A.2002;99(17):11393-11398.
9. Carmeliet P, Moons L, Luttun A, et al.Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.Nat Med.2001;7(5):575-583.
10. Takahashi H, Shibuya M.The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.Clin Sci (Lond).2005;109(3): 227-241.
11. Zhao B, Smith G, Cai J, Ma A, Boulton M.Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2.Br J Ophthalmol.2007;91(4):538-545.
12. Zhao B, Ma A, Cai J, Boulton M.VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells.Br J Ophthalmol.2006;90(8):1052-1059.
13. Puddu A, Sanguineti R, Durante A, Nicolò M, Viviani GL.Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization.Mol Vis.2012;18:2509-2517.
14. Klettner A, Recber M, Roider J.Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.Graefes Arch Clin Exp Ophthalmol.2014;252(10): 1593-1598.
15. Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J.Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.Graefes Arch Clin Exp Ophthalmol.2009;247(12):1601-1608.
16. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D’Amore PA.An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.Proc Natl Acad Sci USA.2009;106(44):18751-18756.
17. Livak KJ, Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods.2001;25(4):402-408.
18. Ke Q, Costa M.Hypoxia-inducible factor-1 (HIF-1).Mol Pharmacol.2006;70(5):1469-1480.
19. Ammar DA, Mandava N, Kahook MY.The effects of aflibercept on the viability and metabolism of ocular cells in vitro.Retina.2013;33(5):1056-1061.
20. Malik D, Tarek M, Caceres del Carpio J, et al.Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.Br J Ophthalmol.2014;98(Suppl 1):i11-i16.
21. Schnichels S, Hagemann U, Januschowski K, et al.Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.Br J Ophthalmol.2013;97(7):917-923.
22. Byeon SH, Lee SC, Choi SH, et al.Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt.Invest Ophthalmol Vis Sci.2010;51(2):1190-1197.
23. Gerber HP, McMurtrey A, Kowalski J, et al.Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.Requirement for Flk-1/KDR activation.J Biol Chem.1998;273(46):30336-30343.
24. Zhao B, Cai J, Boulton M.Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2.Microvasc Res.2004;68(3):239-246.
25. Yao YG, Yang HS, Cao Z, Danielsson J, Duh EJ.Upregulation of placental growth factor by vascular endothelial growth factor via a post-transcriptional mechanism.FEBS Lett.2005;579(5):1227-1234.
26. Zhang F, Tang Z, Hou X, et al.VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis.Proc Natl Acad Sci USA.2009;106(15):6152-6157.